adjuvant chemoradiotherapy
Showing 1 - 25 of 5,704
Esophageal Cancer Trial (Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B), Adjuvant chemoradiotherapy)
Not yet recruiting
- Esophageal Cancer
- Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
- Adjuvant chemoradiotherapy
- (no location specified)
Dec 19, 2022
Chemo Effect, Rectal Cancer Trial in Guangzhou (Radical total mesorectal excision, Salavge Adjuvant Chemoradiotherapy)
Recruiting
- Chemotherapy Effect
- Rectal Cancer
- Radical total mesorectal excision
- Salavge Adjuvant Chemoradiotherapy
-
Guangzhou, Guangdong, ChinaGastrointestinal Hospital, Sun Yat-sen University
Sep 12, 2023
Uterine Cervical Tumors, Chemoradiotherapy, Adjuvant Chemo Trial in Liuzhou (paclitaxel combined with platinum)
Recruiting
- Uterine Cervical Neoplasms
- +2 more
- paclitaxel combined with platinum
-
Liuzhou, Guangxi, Chinathe Fourth Affiliated Hospital of Guangxi Medical University
Feb 16, 2023
Cervical Cancer Trial in Suzhou (Chemoradiotherapy + Adjuvant chemo and Zimberelimab, Chemoradiotherapy (small pelvic) +
Recruiting
- Cervical Cancer
- Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
- Chemoradiotherapy (small pelvic) + Zimberelimab
-
Suzhou, Jiangsu, ChinaThe Affiliated Suzhou Hospital of Nanjing Medical University
May 14, 2023
Cervical Cancer Trial in Shanghai (adjuvant concurrent chemoradiotherapy, radiotherapy)
Recruiting
- Cervical Cancer
- adjuvant concurrent chemoradiotherapy
- radiotherapy
-
Shanghai, Shanghai, China
- +1 more
Sep 14, 2022
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
Esophageal Squamous Cell Carcinoma Trial in Taipei City (Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Taipei City, TaiwanNational Taiwan University Hospital
Jun 5, 2022
Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (drug, procedure, radiation)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Nab-paclitaxel, cisplatin and Pembrolizumab combination
- +3 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Feb 28, 2022
Glioblastoma Trial in Oklahoma City (OKN 007, Temozolomide, Photon/Proton IMRT)
Recruiting
- Glioblastoma
- OKN 007
- +2 more
-
Oklahoma City, OklahomaStephenson Cancer Center, University of Oklahoma Health Sciences
Jun 17, 2022
Local Advanced High Risk Nasopharyngeal Carcinoma Trial in Guangzhou (IMRT combine with cisplatin concurrent chemo, IMRT combine
Recruiting
- Local Advanced High Risk Nasopharyngeal Carcinoma
- IMRT combine with cisplatin concurrent chemotherapy
- IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Apr 9, 2022
Gastric Cancer Trial in Wuhan (DC, concurrent chemoradiotherapy with 5-FU/CF, radiation)
Recruiting
- Gastric Cancer
- DC
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jan 29, 2022
Rectal Tumors Trial in Larissa (Neoadjuvant Chemoradiotherapy, Adjuvant Chemotherapy, Consolidation Chemotherapy)
Not yet recruiting
- Rectal Neoplasms
- Neoadjuvant Chemoradiotherapy
- +2 more
-
Larissa, GreeceDepartment of Surgery, University Hospital of Larissa
Aug 10, 2022
Resectable Pancreatic Cancer, Adjuvant Chemoradiotherapy, Surgery Trial in Shanghai (other, drug, radiation)
Recruiting
- Resectable Pancreatic Cancer
- +2 more
- Follow-up only
- +3 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital Fudan University
Feb 1, 2021
Esophageal Squamous Cell Carcinoma Trial in Fuzhou (adjuvant treatment)
Recruiting
- Esophageal Squamous Cell Carcinoma
- adjuvant treatment
-
Fuzhou, Fujian, ChinaFujian Medical University Union Hospital
Nov 10, 2021
Nasopharyngeal Carcinoma Trial in Shanghai (gemcitabine and cisplatin (Induction and adjuvant chemo), IMRT, gemcitabine and
Recruiting
- Nasopharyngeal Carcinoma
- gemcitabine and cisplatin (Induction and adjuvant chemotherapy)
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 16, 2022
Malignant Tumor of Lacrimal Drainage Structure Trial in Shanghai (Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by
Recruiting
- Malignant Tumor of Lacrimal Drainage Structure
- Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery
- Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy
-
Shanghai, ChinaFudan Eye & ENT Hospital
Mar 22, 2022
Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)
Recruiting
- Nasopharyngeal Carcinoma
-
Beijing, Beijing, ChinaNational Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022
Gastric Cancer Trial in Netherlands (drug, procedure, radiation)
Recruiting
- Gastric Cancer
- Docetaxel
- +6 more
-
Leeuwarden, Friesland, Netherlands
- +27 more
Jan 20, 2022
Gastric Cancer Trial in Shanghai (PD-1 inhibitor, Oxaliplatin, Capecitabine)
Recruiting
- Gastric Cancer
- PD-1 inhibitor
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 1, 2021
"Watch and Wait" After Neo-adjuvant Chemoradiotherapy for
Recruiting
- Rectal Cancer
-
Bergen, Norway
- +6 more
Dec 15, 2020
Squamous Cell Carcinoma of the Oral Cavity Trial in Bebington (Nivolumab, Surgery, Radiotherapy, Nivolumab, Surgery,
Active, not recruiting
- Squamous Cell Carcinoma of the Oral Cavity
- Nivolumab, Surgery, Radiotherapy
- Nivolumab, Surgery, Chemoradiotherapy
-
Bebington, United KingdomClatterbridge Cancer Centre NHS Foundation Trust
Jan 4, 2021
Nasopharyngeal Carcinoma Trial (GP+Peramprizumab+Anlotinib, GP+Peramprizumab)
Not yet recruiting
- Nasopharyngeal Carcinoma
- (no location specified)
Jan 14, 2022